Baird Starts Onyx Pharmaceuticals (ONXX) at Outperform
More News related to ONXX
- Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
- Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
- Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
Robert W. Baird initiates coverage on Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) with an Outperform rating and $40 price target, citing dissipation of key overhangs, near-term commercial upside and valuation.
The firm said, "We are near-term buyers of ONXX shares as we think the dissipation of a number of key overhangs coupled with meaningful near-term commercial upside opportunities could lift shares in coming quarters. Coupling this with a compelling valuation (2009E EV/Sales of roughly half the level its mid-cap peers), we are buyers into the high-$30 range."
Baird notes ONXX is down 17% YTD on fears over flagship Nexavar's prospects. The said these risk are overblown.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
New CoverageStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
